Allianz Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,080
| Closed | -$204K | – | 2072 |
|
|
2025
Q4 | $204K | Buy |
+1,080
| New | +$208K | ﹤0.01% | 1939 |
|
|
2024
Q2 | – | Sell |
-7,000
| Closed | -$512K | – | 2202 |
|
|
2024
Q1 | $512K | Sell |
7,000
-3,000
| -30% | -$221K | ﹤0.01% | 1617 |
|
|
2023
Q4 | $714K | Buy |
10,000
+2,900
| +41% | +$171K | ﹤0.01% | 1731 |
|
|
2023
Q3 | $425K | Hold |
7,100
| – | – | ﹤0.01% | 1982 |
|
|
2023
Q2 | $512K | Buy |
+7,100
| New | +$533K | ﹤0.01% | 1732 |
|
|
2021
Q2 | – | Sell |
-4,016
| Closed | -$382K | – | 2440 |
|
|
2021
Q1 | $382K | Buy |
+4,016
| New | +$380K | ﹤0.01% | 1989 |
|
|
2019
Q1 | – | Sell |
-62,927
| Closed | -$5.33M | – | 2738 |
|
|
2018
Q4 | $5.33M | Buy |
62,927
+33,616
| +115% | +$3.58M | 0.01% | 1381 |
|
|
2018
Q3 | $5.02M | Buy |
29,311
+4,421
| +18% | +$667K | ﹤0.01% | 1558 |
|
|
2018
Q2 | $3.22M | Sell |
24,890
-19,516
| -44% | -$2.18M | ﹤0.01% | 1737 |
|
|
2018
Q1 | $4.58M | Sell |
44,406
-17,290
| -28% | -$1.71M | ﹤0.01% | 1573 |
|
|
2017
Q4 | $5.27M | Sell |
61,696
-26,977
| -30% | -$2.34M | ﹤0.01% | 1596 |
|
|
2017
Q3 | $7.53M | Sell |
88,673
-21,052
| -19% | -$1.67M | 0.01% | 1430 |
|
|
2017
Q2 | $8.31M | Buy |
109,725
+6,790
| +7% | +$475K | 0.01% | 1378 |
|
|
2017
Q1 | $6.8M | Sell |
102,935
-21,684
| -17% | -$1.43M | 0.01% | 1495 |
|
|
2016
Q4 | $7.9M | Sell |
124,619
-84,120
| -40% | -$5.31M | 0.01% | 1467 |
|
|
2016
Q3 | $13.3M | Buy |
208,739
+3,569
| +2% | +$262K | 0.01% | 1187 |
|
|
2016
Q2 | $15.3M | Sell |
205,170
-211,636
| -51% | -$15.7M | 0.02% | 1043 |
|
|
2016
Q1 | $27.8M | Buy |
416,806
+11,678
| +3% | +$710K | 0.03% | 619 |
|
|
2015
Q4 | $27.4M | Buy |
405,128
+52,372
| +15% | +$3.23M | 0.03% | 607 |
|
|
2015
Q3 | $18.8M | Sell |
352,756
-73,256
| -17% | -$4.44M | 0.02% | 730 |
|
|
2015
Q2 | $26.8M | Sell |
426,012
-149,366
| -26% | -$8.15M | 0.03% | 661 |
|
|
2015
Q1 | $27.7M | Sell |
575,378
-81,501
| -12% | -$3.12M | 0.03% | 581 |
|
|
2014
Q4 | $21.8M | Buy |
656,879
+17,149
| +3% | +$558K | 0.02% | 670 |
|
|
2014
Q3 | $18.6M | Buy |
639,730
+194,155
| +44% | +$6.44M | 0.02% | 651 |
|
|
2014
Q2 | $17.3M | Sell |
445,575
-2,994
| -0.7% | -$121K | 0.02% | 604 |
|
|
2014
Q1 | $18.7M | Buy |
448,569
+62,692
| +16% | +$2.61M | 0.02% | 571 |
|
|
2013
Q4 | $12.7M | Buy |
385,877
+100,854
| +35% | +$3.29M | 0.02% | 648 |
|
|
2013
Q3 | $7.7M | Buy |
285,023
+12,353
| +5% | +$348K | 0.01% | 770 |
|
|
2013
Q2 | $6.36M | Buy |
+272,670
| New | +$4.9M | 0.01% | 797 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Allianz Asset Management's LGND Position: Q1 2026 in Review
Allianz Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 1,080 shares — an estimated $204K sold.
Allianz Asset Management first reported a position in LGND in Q2 2013 and held it in 29 quarters. The position peaked at $27.8M in Q1 2016. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Allianz Asset Management reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Allianz Asset Management sold 1,080 Ligand Pharmaceuticals shares in Q1 2026, an estimated $204K.
- Allianz Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 29 quarters.
- Allianz Asset Management's Ligand Pharmaceuticals position peaked at $27.8M in Q1 2016.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.